The Business Model Canvas
Key Partners
- Cambridge Judge Business
School
- The Tech Healx
- Business Accelerator
- The patients with rare disease
- Pharmaceutical companies
- Partnership
- Medical Partitioner
- Developed the world’s most
efficient AI for discovering and
translating treatments for rare
diseases
Key Activities
- Marketing
- One drug, Soliris, used in the
treatment of paroxysmal nocturnal
hemoglobinuria
- Specializes of recovery to the
patient have a rarest disease.
- Giving an incentive to the other
companies
- They required asset sharing,
personalization, and collaborative
ecosystem
Key Resources
- They compared the amount of
drug data currently provided to
sufferers of rare diseases.
- They covered 1,000 of the
7,000 rare diseases that have
formal advocacy groups worldwide.
- Looking at the proportion of
known data on rare-disease-
relevant drugs.
- Some 350 million people,95%
of whom currently get not even
reasonably relevant drug
recommendations.
- If an expensive treatment
doesn’t work for a patient, the
company responsible can be forced
to reimburse NHS providers for its
cost.
Designed for:
Value Propositions
- Big data technology and analytics
- Treatment of patients with rare
Designed by: Date: Version:
Customer Relationships Customer Segments
- The benefactors of this business - Benefactors are the patients and
are the patients and the especially the pharmaceutical
pharmaceutical companies because companies. Cooperation with Healx
this will be going to be a great help will provide a great deal like medical
in medical research in rare - data information, money or funding,
diseases. The unity of and a less medical price charges
pharmaceutical companies, various that will change the course of
of rare - diseases will be able to be medical innovation.
cured in a matter of years because
of the information’s they have
given to the database of the Healx.
Healx struggled to get pharma
companies to join the platform;
they were concerned that their
treatment data would leak to
competitors. But the Healx team
spotted an opportunity to give
companies an incentive so they can
rest assure. This business is costing
a million pounds by the
investments from several global
funds and manages to help the
pharmaceutical companies to
predict such failures with high
accuracy, potentially saving millions
of pounds a year.
Channels
- Personal medicine
 Cost Structure Revenue Streams

- The important cost was taking some data in other companies and paying some incentives for - The customers are willing to pay because of the services and the more accurate results and
their data or ideas. information about them.

- The most expensive key resources were the data about everything and especially the start off - They currently paying for the information and descriptions
place.
- They have revenue in a way that while they researching many data about things they gain and
- The most expensive key activities was the developed machine. collected data. And making cure for the rare disease and they earn money and revenue their
place.

This work is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported License. To view a copy of this license, visit:
http://creativecommons.org/licenses/by-sa/3.0/ or send a letter to Creative Commons, 171 Second Street, Suite 300, San Francisco, California, 94105, USA.

DESIGNED By: Strategyzer AG

The makers of Business Model Generation and Strategyzer strategyzer.com